MDS Pharma Services promotes Terry Lenehan, Ph.D., to vice president, clinical operations, Europe
(March 12, 2001; Montreal, Quebec) — MDS Pharma Services is pleased to announce the promotion of Terry J. Lenehan, Ph.D., to the position of vice president, clinical operations, Europe. In his new role, Dr. Lenehan will be responsible for all early clinical research operations in Europe. With facilities in Belfast, Munich and Hamburg, housing 148 beds of more than 750 beds in facilities worldwide, MDS Pharma Services provides services ranging from clinical pharmacology to data management, statistics and PK/PD analysis and access to a large base of normal healthy volunteers and special populations.
Dr. Lenehan possesses more than 22 years of clinical research experience. He joined MDS Pharma Services (then Harris Laboratories) in 1993 as director of clinical research at their facility in Belfast, Northern Ireland. He later served as vice president, research and development, Europe. Prior to joining MDS Pharma Services, Dr. Lenehan served as general manager, clinical operations, UK/ Ireland, for GH Besselaar Associates. Prior experience also includes several years with the Institute of Clinical Pharmacology, Norbrook Laboratories, and Hoffmann-La Roche.
"Terry Lenehan has been a key member of our team in Belfast and Europe for a number of years," said Jerry Merritt, senior vice president, early clinical research, MDS Pharma Services. "With this promotion, he will be able to apply his experience to the broader European market and develop our client base for early clinical research studies, an area in which our capabilities and expertise are simply unmatched."
Dr. Lenehan is an executive council member of the Association of Independent Clinical Research Contractors (AICRC), the professional body of CROs in the UK. He is also a visiting lecturer at Queen’s University, the University of Surrey and the University of Ulster.
Dr. Lenehan has authored numerous articles and abstracts published in international journals. He has also presented papers at international scientific and medical conferences over many years. He is a member of the British Institute for Regulatory Affairs, the Institute of Directors (London), the Drug Information Association (DIA), the American Association of Pharmaceutical Scientists, the Association of Pharmacologists in the Pharmaceutical Industry and the British Pharmacological Society.
Dr. Lenehan studied at Trinity College, Dublin where he received a BA (Mod) in natural sciences, followed by an MA in immunology/microbiology and later was conferred with a Ph.D. in clinical immunology/haematology. He continued to work at Trinity as a post-doctoral fellow before beginning his career in clinical pharmacology in the pharmaceutical industry.
MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With facilities in more than 17 countries, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process: discovery, preclinical, early clinical research (phases I-IIa), bioanalytical, global clinical research (phases IIb-IV), and central lab.
MDS Pharma Services is part of MDS Inc. (TSE: MDS; NYSE: MDZ), an international health and life sciences company. In many of its products and services, it is among the largest and most respected companies in the world. At MDS, the focus is on fighting disease. It does this by providing laboratory testing, imaging products, research services to speed discovery and development of new drugs, therapy systems for planning and delivery of cancer treatments, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. MDS employs more than 10,000 highly skilled people in its global operations on five continents. Detailed information about the company is available at the MDS Web site at www.mdsintl.com or by calling 1-888-MDS-7222, 24 hours a day.
